Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA Animal Free,Azide Free,Carrier Free,ExactAb™,Low Endotoxin,Recombinant,Validated for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C,Avoid repeated freezing and thawing Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Dacetuzumab (anti-CD40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab (anti-CD40) kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab (anti-CD40) can be used for multiple myeloma research.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
Dacetuzumab (anti-CD40) (Ab183418) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD40 with Dacetuzumab (anti-CD40) (Ab183418) conjugated with biotin (right panel) compared with Human IgG (Biotin) (Ab180314) - Isotype Control (left panel) and detected with SA-PE (rp156150).
Dacetuzumab (anti-CD40) (Ab183418) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD40 (red) with Dacetuzumab (anti-CD40) (Ab183418) conjugated with biotin and detected with SA-PE (rp156150). Blue - Isotype control, Human IgG (Biotin) (Ab180314). Black - Unlabelled control, cells without incubation with primary antibody.
Dacetuzumab (anti-CD40) (Ab183418) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD40 (red) with Dacetuzumab (anti-CD40) (Ab183418). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Dacetuzumab (anti-CD40) (Ab183418) - ELISA
Immobilized Recombinant Human CD40 protein (rp183577) at 1.0 μg/mL can bind Dacetuzumab (anti-CD40) (Ab183418) with the EC₅₀ of 30.11 ng/mL.
Dacetuzumab (anti-CD40) (Ab183418) - SEC
The purity of Dacetuzumab (anti-CD40) (Ab183418) is more than 95% verified by HPLC.
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Fecha | Articulo |
|---|---|---|---|
 ZJ24F0910138 | Certificate of Analysis | Jun 17, 2026 | Ab183418 |
| ZJ24F0910139 | Certificate of Analysis | Jun 17, 2026 | Ab183418 |
| ZJ24F0910140 | Certificate of Analysis | Jun 17, 2026 | Ab183418 |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Animal Free grade guide → View Carrier Free grade guide → View Recombinant grade guide → View Validated grade guide → View ExactAb™ grade guide → View Low Endotoxin grade guide → View Azide Free grade guide →
